Copyright
©The Author(s) 2019.
World J Diabetes. Feb 15, 2019; 10(2): 114-132
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
Table 15 Change in serum low-density lipoprotein cholesterol in individual studies
| Study | Serum low-density lipoprotein cholesterol (mg/dL) | P value | P value between groups | ||
| Group | Baseline | Study completion | |||
| Kuchay et al[11] | Empagliflozin | 112.0 (35.0) | 95.0 (22.0) | 0.018 | 0.512 |
| Control | 114.0 (30.0) | 96.0 (17.0) | 0.001 | ||
| Ito et al[12] | Ipragliflozin | 108.3 (36.2) | 110.7 (40.1) | Non-significant | 0.057 |
| Pioglitazone | 104.0 (27.9) | 114.6 (29.5) | < 0.05 | ||
| Eriksson et al[14] | Placebo | 98.2 (34.4) | +1.6 (15.5)1 | - | - |
| Omega-3 CA | 111.8 (34.4) | +2.3 (17.4)1 | - | Non-significant2 | |
| Dapagliflozin | 109.4 (34.8) | +7.7 (20.5)1 | - | Non-significant2 | |
| O + D | 88.9 (23.2) | +5.8 (21.7)1 | - | Non-significant2 | |
| Ohki et al[15] | Ipragliflozin | 113.0 (89.0-142.0) | 103.0 (92.0-122.0) | 0.08 | - |
| Seko et al[16] | SGLT-2 inhibitor | 119.2 (5.8) | 119.8 (5.7) | 0.943 | - |
| Sitagliptin | 112.9 (4.9) | 127.1 (8.8) | 0.063 | ||
| Sumida et al[18] | Luseogliflozin | 101.0 (22.4) | 105.0 (24.4) | 0.11 | - |
- Citation: Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes 2019; 10(2): 114-132
- URL: https://www.wjgnet.com/1948-9358/full/v10/i2/114.htm
- DOI: https://dx.doi.org/10.4239/wjd.v10.i2.114